2022
DOI: 10.32604/oncologie.2022.025411
|View full text |Cite
|
Sign up to set email alerts
|

RCN3 Expression Indicates Prognosis in Colorectal Cancers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 22 publications
0
3
0
Order By: Relevance
“…Both MR and CT enterography offer high-resolution imaging, enabling the visualization of small intestinal lesions from multiple perspectives and planes ( Li et al, 2023 ). MR enterography excels in providing clear images of the small intestinal lumen, external structures, and intestinal walls, whilst CT enterography allows the accurate display of morphological details and anatomical relationships between lesions in the small intestine and surrounding tissues ( Ma et al, 2022 ; Wang, Chen & Hu, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…Both MR and CT enterography offer high-resolution imaging, enabling the visualization of small intestinal lesions from multiple perspectives and planes ( Li et al, 2023 ). MR enterography excels in providing clear images of the small intestinal lumen, external structures, and intestinal walls, whilst CT enterography allows the accurate display of morphological details and anatomical relationships between lesions in the small intestine and surrounding tissues ( Ma et al, 2022 ; Wang, Chen & Hu, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…Colorectal cancer (CRC) is the third most frequent malignant tumour of the digestive system with the second highest mortality rate. Recent decades have experienced an increase in the incidence of CRC 1–3 . At present, immunotherapeutic strategies represented by immune checkpoint inhibitors could provide therapeutic options for patients with advanced CRC, though the overall efficacy is not satisfactory 4–6 .…”
Section: Introductionmentioning
confidence: 99%
“…
Colorectal cancer (CRC) is the third most frequent malignant tumour of the digestive system with the second highest mortality rate.Recent decades have experienced an increase in the incidence of CRC. [1][2][3] At present, immunotherapeutic strategies represented by immune checkpoint inhibitors could provide therapeutic options for patients with advanced CRC, though the overall efficacy is not satisfactory. [4][5][6] Metastasis is a process during which cancer cells at the primary lesion spread to surrounding tissues and distant organs and distant metastasis is a major cause of cancer death.
…”
mentioning
confidence: 99%
“…The standard treatment for CRC is surgery, chemotherapy and radiotherapy [ [6] , [7] , [8] ], but there is limited variation between the effectiveness of these treatments and long-term survival, particularly for patients with metastatic CRC, where approximately 70%–75% of patients survive more than one year and 30%–35% of patients survive more than three years, compared to less than five years after diagnosis [ 9 , 10 ]. The molecular landscape of CRC on histological and clinical information of each patients differs greatly [ [11] , [12] , [13] ]. Therapeutic decisions based on molecular subtypes might be a promising strategy for treating CRC, and development of new drugs in a way that targets CRC subtypes has the potential to transform drug discovery research [ 14 ].…”
Section: Introductionmentioning
confidence: 99%